144 related articles for article (PubMed ID: 15912142)
1. Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms.
Fentress HM; Grinde E; Mazurkiewicz JE; Backstrom JR; Herrick-Davis K; Sanders-Bush E
Pharmacogenomics J; 2005; 5(4):244-54. PubMed ID: 15912142
[TBL] [Abstract][Full Text] [Related]
2. A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling.
Berg KA; Dunlop J; Sanchez T; Silva M; Clarke WP
J Pharmacol Exp Ther; 2008 Mar; 324(3):1084-92. PubMed ID: 18065501
[TBL] [Abstract][Full Text] [Related]
3. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution.
Okada M; Northup JK; Ozaki N; Russell JT; Linnoila M; Goldman D
Mol Psychiatry; 2004 Jan; 9(1):55-64. PubMed ID: 14699441
[TBL] [Abstract][Full Text] [Related]
4. Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.
Westphal RS; Sanders-Bush E
Mol Pharmacol; 1996 Mar; 49(3):474-80. PubMed ID: 8643087
[TBL] [Abstract][Full Text] [Related]
5. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
Rauser L; Savage JE; Meltzer HY; Roth BL
J Pharmacol Exp Ther; 2001 Oct; 299(1):83-9. PubMed ID: 11561066
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of 5HT(2C) receptor-mediated ERK1/2 phosphorylation: agonist-specific activation pathways and the impact of RNA editing.
Werry TD; Stewart GD; Crouch MF; Watts A; Sexton PM; Christopoulos A
Biochem Pharmacol; 2008 Nov; 76(10):1276-87. PubMed ID: 18812172
[TBL] [Abstract][Full Text] [Related]
7. Neuroimaging and 5-HT2C receptor polymorphism: a HMPAO-SPECT study in healthy male probands using mCPP-challenge of the 5-HT2C receptor.
Kühn KU; Joe AY; Meyer K; Reichmann K; Maier W; Rao ML; Reinhardt MJ; Biersack HJ; Quednow BB
Pharmacopsychiatry; 2004 Nov; 37(6):286-91. PubMed ID: 15551195
[TBL] [Abstract][Full Text] [Related]
8. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor.
Brüss M; Kiel S; Bönisch H; Kostanian A; Göthert M
Neurochem Int; 2005 Aug; 47(3):196-203. PubMed ID: 15896881
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists.
Westphal RS; Sanders-Bush E
Mol Pharmacol; 1994 Nov; 46(5):937-42. PubMed ID: 7969083
[TBL] [Abstract][Full Text] [Related]
10. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
[TBL] [Abstract][Full Text] [Related]
11. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
[TBL] [Abstract][Full Text] [Related]
12. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
[TBL] [Abstract][Full Text] [Related]
13. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
14. Regulation of serotonin 5-HT2C receptors by chronic ligand exposure.
Devlin MG; Smith NJ; Ryan OM; Guida E; Sexton PM; Christopoulos A
Eur J Pharmacol; 2004 Sep; 498(1-3):59-69. PubMed ID: 15363976
[TBL] [Abstract][Full Text] [Related]
15. Mutagenesis analysis of the serotonin 5-HT2C receptor and a Caenorhabditis elegans 5-HT2 homologue: conserved residues of helix 4 and helix 7 contribute to agonist-dependent activation of 5-HT2 receptors.
Xie J; Dernovici S; Ribeiro P
J Neurochem; 2005 Jan; 92(2):375-87. PubMed ID: 15663485
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of agonist binding on human 5-HT2C receptor isoforms.
Quirk K; Lawrence A; Jones J; Misra A; Harvey V; Lamb H; Revell D; Porter RH; Knight AR
Eur J Pharmacol; 2001 May; 419(2-3):107-12. PubMed ID: 11426831
[TBL] [Abstract][Full Text] [Related]
17. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization.
Westphal RS; Backstrom JR; Sanders-Bush E
Mol Pharmacol; 1995 Aug; 48(2):200-5. PubMed ID: 7651352
[TBL] [Abstract][Full Text] [Related]
18. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Cussac D; Newman-Tancredi A; Quentric Y; Carpentier N; Poissonnet G; Parmentier JG; Goldstein S; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
[TBL] [Abstract][Full Text] [Related]
19. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C).
Lappalainen J; Zhang L; Dean M; Oz M; Ozaki N; Yu DH; Virkkunen M; Weight F; Linnoila M; Goldman D
Genomics; 1995 May; 27(2):274-9. PubMed ID: 7557992
[TBL] [Abstract][Full Text] [Related]
20. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
